Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,174,544
  • Shares Outstanding, K 108,060
  • Annual Sales, $ 5,872 M
  • Annual Income, $ 1,199 M
  • 36-Month Beta 1.26
  • Price/Sales 6.84
  • Price/Cash Flow 23.44
  • Price/Book 5.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 4.89
  • Number of Estimates 2
  • High Estimate 5.03
  • Low Estimate 4.75
  • Prior Year 3.32
  • Growth Rate Est. (year over year) +47.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
360.72 +3.75%
on 07/18/18
401.50 -6.78%
on 08/02/18
+8.83 (+2.42%)
since 07/17/18
3-Month
291.10 +28.57%
on 05/23/18
401.50 -6.78%
on 08/02/18
+66.26 (+21.51%)
since 05/17/18
52-Week
281.89 +32.77%
on 05/09/18
505.49 -25.96%
on 09/01/17
-89.76 (-19.34%)
since 08/17/17

Most Recent Stories

More News
Regeneron, Teva Announce Positive Data on Osteoarthritis Drug

Regeneron (REGN) along with partner Teva announces positive top-line results from a late-stage candidate on fasinumab in patients with chronic pain from osteoarthritis of the knee or hip.

GILD : 72.92 (-3.53%)
TEVA : 24.22 (+0.46%)
REGN : 374.26 (+0.67%)
SNY : 42.04 (+1.92%)
FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept)...

REGN : 374.26 (+0.67%)
Inovio Pharmaceuticals Initiates Dosing in HIV Vaccine Study

Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.

ILMN : 325.88 (-0.34%)
GILD : 72.92 (-3.53%)
INO : 4.43 (-1.56%)
REGN : 374.26 (+0.67%)
Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from a Phase 3, randomized, double-blind,...

TEVA : 24.22 (+0.46%)
REGN : 374.26 (+0.67%)
Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

Data include final primary efficacy results and an interim safety analysis

TEVA : 24.22 (+0.46%)
REGN : 374.26 (+0.67%)
17.4% Return Seen to Date on SmarTrend Regeneron Pharm Call (REGN)

SmarTrend identified an Uptrend for Regeneron Pharm (NASDAQ:REGN) on June 4th, 2018 at $309.88. In approximately 2 months, Regeneron Pharm has returned 17.39% as of today's recent price of $363.75.

REGN : 374.26 (+0.67%)
Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD

Regeneron (REGN) suffers setback as the FDA issues a CRL to its application for label expansion of Eylea for wet AMD with a modified 12-week dosing schedule.

BAYRY : 22.7300 (+3.98%)
NVS : 83.04 (+1.03%)
REGN : 374.26 (+0.67%)
SNY : 42.04 (+1.92%)
Time to Focus on Regeneron Pharmaceuticals (REGN) for Strong Earnings Growth Potential

Regeneron Pharmaceuticals (REGN) seems well-positioned for future earnings growth and it is seeing rising earnings estimates as well, coupled with a solid Zacks Rank.

REGN : 374.26 (+0.67%)
Regeneron Provides Regulatory Update on EYLEA® (aflibercept) Injection sBLA in Wet Age-Related Macular Degeneration

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that due to ongoing labeling discussions the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding...

REGN : 374.26 (+0.67%)
Momenta (MNTA) Earnings and Revenues Lag Estimates in Q2

Momenta (MNTA) reports wider-than-expected Q2 loss. Sales miss estimates too. The focus now is on the outcome of the ongoing strategic review including a possible sale of the biosimilar business.

MYL : 38.15 (+0.79%)
MNTA : 27.60 (+2.79%)
TEVA : 24.22 (+0.46%)
REGN : 374.26 (+0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade REGN with:

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

2nd Resistance Point 381.79
1st Resistance Point 378.02
Last Price 374.26
1st Support Level 370.33
2nd Support Level 366.41

See More

52-Week High 505.49
Fibonacci 61.8% 420.07
Fibonacci 50% 393.69
Last Price 374.26
Fibonacci 38.2% 367.31
52-Week Low 281.89

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar